Value Sense
BSX
Boston Scientific Corporation (BSX)
Last Price$104.91.0%
Market Cap$154.5B
Intrinsic value score
7/10
Good
Intrinsic value
$34.2
DCF value - $14.7 Relative value - $53.7
Overvalued
67.4%
LTM P/E
83.5x
Peer set median 32.4x
Discount rate
7.3%
BSX
is 67.4% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

BSX Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 BSX Relative Value is $53.7, which is overvalued by 48.8%, compared to current share price of $104.9.
DCF Value vs Current Share Price
As of Mar 03, 2025 BSX DCF Value is $14.4, which is overvalued by 86.3%, compared to current share price of $104.9.
Methodology
Price per share, $
BSX
Intrinsic value$34.2
Overvalued by67.4%
Current share price
104.9
Relative value
53.7
DCF value
14.4

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

BSX Historical Intrinsic Value

Crunching data... Almost there!

BSX vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Boston Scientific Corporation logo
Boston Scientific CorporationBSX
(67.4%)
17.6%
16.7%
11.1%
Median Peer Set
4.1%
126.3%
12.7%
Insulet Corporation logo
Insulet CorporationPODD
(50.7%)
30.0%
4,364.6%
12.2%
DexCom, Inc. logo
DexCom, Inc.DXCM
(49.8%)
11.3%
(1.4%)
14.3%
Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
(24.2%)
(9.4%)
202.2%
76.7%
Stryker Corporation logo
Stryker CorporationSYK
(22.7%)
10.2%
(5.8%)
13.2%
STERIS plc logo
STERIS plcSTE
(10.4%)
3.6%
257.9%
7.4%
Align Technology, Inc. logo
Align Technology, Inc.ALGN
8.5%
3.4%
26.0%
11.5%
Medtronic plc logo
Medtronic plcMDT
21.5%
3.6%
(2.1%)
11.4%
Abbott Laboratories logo
Abbott LaboratoriesABT
24.5%
4.6%
134.5%
31.9%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
72.0%
6.5%
253.2%
13.8%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
146.8%
(0.8%)
118.1%
(3.9%)

Explore more intrinsic value tools hub for BSX

Peter Lynch Fair Value
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Earnings growth model
DCF value calculator
Discount rate
Peter Lynch charts
Reverse DCF
Relative Value

FAQ

What is Boston Scientific Corporation intrinsic value?

As of Mar 03, 2025, Boston Scientific Corporation Intrinsic Value is $34.2. This suggests it may be overvalued by 67.4% compared to its current price of around $104.9.

What is Boston Scientific Corporation DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Boston Scientific Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $14.4. This suggests it may be overvalued by 86.3% to its current price of around $104.9, using a discount rate of 7.3% and terminal growth rate of 3.0%.

Is Boston Scientific Corporation overvalued or undervalued?

Boston Scientific Corporation is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $34.2, compared to a market price of around $104.9. This suggests a potential overvaluation of 67.4%.